Skip to main content
Dryad

A pharmacoeconomic study of post-exposure prophylaxis strategies for influenza virus infections in Japan

Data files

Aug 20, 2024 version files 13.76 KB

Click names to download individual files

Abstract

Background Vaccines can prevent influenza (flu) infections and are cost-effective for society and healthcare. However, the cost-effectiveness of post-exposure prophylaxis as a follow-up strategy is unclear. This study evaluates the cost–utility of post-exposure prophylaxis and treatment strategies with neuraminidase inhibitors (NIs) and a cap-dependent endonuclease inhibitor (EI) for flu infections from the perspective of healthcare costs in Japan. 

Research design and methods A base-case analysis was used to compare oseltamivir, zanamivir, and laninamivir for Nls and baloxavir marboxil for EI. The costs of the first visit to a physician and pharmacy were excluded because of out-of-pocket for post-exposure prophylaxis in Japan. Direct medical costs included the second physician visit, pharmacy and hospital admission expenses, and drug prices, based on the 2020 Japanese Medical Fee Index. EQ-5D-5L questionnaires were utilized to measure healthy participants’ quality of life scores, with a time horizon of 14 days. Deterministic and probabilistic sensitivity analyses were conducted.

Results We find baloxavir marboxil as the post-exposure prophylaxis agent and laninamivir as the treatment agent to be the most cost-effective strategy in Japan, followed by oseltamivir as the post-exposure prophylaxis agent and zanamivir as the treatment agent.

Conclusions The study concludes that baloxavir marboxil and oseltamivir are cost-effective prophylactic agents for flu from the perspective of healthcare costs in Japan. The strategy of baloxavir marboxil as the post-exposure prophylaxis agent and laninamivir as the treatment agent is the most cost-effective in Japan.